Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

Diabetes Mellitus, Type 2 / drug therapy Glucagon-Like Peptide-1 Receptor / agonists Glucagon-Like Peptides / adverse effects Humans Hypoglycemic Agents / adverse effects Incretins / adverse effects Injections, Subcutaneous Treatment Outcome
Cardiovascular Efficacy Glucagon-like peptide-1 receptor agonist Semaglutide, SUSTAIN Type 2 diabetes

Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
10 2019
Historique:
received: 27 09 2018
revised: 06 12 2018
accepted: 16 12 2018
pubmed: 8 1 2019
medline: 28 2 2020
entrez: 8 1 2019
Statut: ppublish

Résumé

In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications. Guidelines recommend treatment goals targeting HbA

Identifiants

DOI: 10.1016/j.diabet.2018.12.001 PMID: 30615985
pubmed: 30615985
pii: S1262-3636(18)30222-2
doi: 10.1016/j.diabet.2018.12.001
pii:
doi:

Substances chimiques

Glucagon-Like Peptide-1 Receptor 0
Hypoglycemic Agents 0
Incretins 0
semaglutide 53AXN4NNHX
Glucagon-Like Peptides 62340-29-8

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-418

Informations de copyright

Copyright © 2018. Published by Elsevier Masson SAS.

Auteurs

V R Aroda (VR)

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: varoda@bwh.harvard.edu.

A Ahmann (A)

Harold Schnitzer Diabetes Health Center at Oregon Health and Science University, Portland, OR, USA. Electronic address: ahmanna@ohsu.edu.

B Cariou (B)

L'institut du thorax, CHU de Nantes, CIC 1413, Inserm, Nantes, France. Electronic address: bertrand.cariou@univ-nantes.fr.

F Chow (F)

Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong. Electronic address: b410773@mailserv.cuhk.edu.hk.

M J Davies (MJ)

Diabetes Research Centre, University of Leicester, Leicester, UK. Electronic address: melanie.davies@uhl-tr.nhs.uk.

E Jódar (E)

Hospital Universitario Quirón Salud Madrid, Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid, Spain. Electronic address: esteban.jodar@gmail.com.

R Mehta (R)

Unidad de Investigacón en Enfermedades Metabolicas, Departamento de Endocrinologia y Metablismo, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" Mexico City, Mexico. Electronic address: roopamehta@yahoo.com.

V Woo (V)

Section of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada. Electronic address: vwoo3@shaw.ca.

I Lingvay (I)

UT Southwestern Medical Center, Dallas, TX, USA. Electronic address: Ildiko.Lingvay@UTSouthwestern.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Comparative efficacy, safety, and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone gastrointestinale › Récepteurs des peptides similaires au glucagon › Récepteur du peptide-1 similaire au glucagon › Comparative efficacy, safety, and...
questionsmedicales.fr › Hormones gastrointestinales › Peptides glucagon-like › Comparative efficacy, safety, and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Comparative efficacy, safety, and...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Comparative efficacy, safety, and...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Incrétines › Comparative efficacy, safety, and...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Injections › Injections sous-cutanées › Comparative efficacy, safety, and...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Comparative efficacy, safety, and...